Q3 EPS Estimate for Rigel Pharmaceuticals Cut by Analyst

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a report issued on Wednesday, August 5th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of $0.68 per share for the quarter, down from their previous forecast of $1.18. HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $3.51 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2026 earnings at $0.81 EPS and FY2026 earnings at $2.81 EPS.

RIGL has been the subject of several other reports. Zacks Research downgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, May 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Friday, July 17th. Finally, Citigroup restated a “buy” rating on shares of Rigel Pharmaceuticals in a report on Thursday. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $54.50.

Rigel Pharmaceuticals Trading Down 3.1%

Shares of RIGL stock opened at $39.22 on Friday. Rigel Pharmaceuticals has a 1 year low of $24.95 and a 1 year high of $52.24. The firm’s fifty day simple moving average is $36.68 and its 200 day simple moving average is $32.98. The firm has a market capitalization of $725.57 million, a P/E ratio of 2.40 and a beta of 1.16.

Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.79. Rigel Pharmaceuticals had a return on equity of 22.95% and a net margin of 116.30%.The company had revenue of $78.70 million during the quarter, compared to analysts’ expectations of $55.27 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RIGL. Ruffer LLP acquired a new stake in Rigel Pharmaceuticals in the 4th quarter valued at $1,598,000. Ritholtz Wealth Management raised its stake in Rigel Pharmaceuticals by 961.3% during the fourth quarter. Ritholtz Wealth Management now owns 80,593 shares of the biotechnology company’s stock worth $3,452,000 after acquiring an additional 72,999 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Rigel Pharmaceuticals during the fourth quarter valued at $2,364,000. Hussman Strategic Advisors Inc. bought a new position in shares of Rigel Pharmaceuticals during the fourth quarter valued at $2,249,000. Finally, Empowered Funds LLC acquired a new stake in shares of Rigel Pharmaceuticals in the 1st quarter valued at $2,234,000. 66.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Rigel Pharmaceuticals

In other news, Director Kamil Ali-Jackson sold 2,500 shares of Rigel Pharmaceuticals stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.00, for a total transaction of $87,500.00. Following the sale, the director owned 10,125 shares of the company’s stock, valued at approximately $354,375. This trade represents a 19.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.47% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).